Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Taiho’s Lonsurf Grabs US Priority Review Status for Gastric Cancer
October 29, 2018
- Daiichi Sankyo, Merck KGaA, Pfizer to Collaborate for PI of DS-8201, Bavencio, and DDR Combo
October 29, 2018
- Lemborexant Improves Nighttime Activity in AD Patients with Irregular Sleep-Wake Rhythm Disorder in PII: Eisai
October 29, 2018
- Eisai, Biogen Tout BAN2401’s Clinical Effect Regardless of APOE4 Mutation
October 29, 2018
- Shionogi, Osaka Univ. to Collaborate on Medical Data Science for Effective Use of Real-World Data
October 26, 2018
- Eisai to Offer 3 Rounds of Voluntary Retirement Program, to Cut 100 Jobs in March Next Year
October 26, 2018
- Xofluza Bags US Approval: Shionogi
October 26, 2018
- Tecentriq, Hemlibra Get Off with a Bang, Clear 2018 Targets Already: Chugai
October 25, 2018
- Swiss API Manufacturer Bachem Establishes Japanese Subsidiary
October 25, 2018
- GSK to Cover Cost of Rubella Testing and Vaccination for Employees
October 25, 2018
- AVXS-101 Is Game Changer for SMA Treatment: Novartis Neuroscience Chief
October 24, 2018
- Meiji Seika Pharma Files Safinamide for Parkinson’s Disease in Japan
October 24, 2018
- Regenerative Medicine Product Market to Reach 225 Billion Yen in 2030: Fuji Keizai
October 24, 2018
- Parexel CEO Sees Bright Future for Japan CRO Market
October 23, 2018
- DS-8201 Shows Overall Response Rate of 15.8% in Patients with Colorectal Cancer in Japan-US PI Study: Daiichi Sankyo
October 23, 2018
- Hisamitsu Begins Japan PII Study of Hyperhidrosis Treatment
October 23, 2018
- Eisai, MSD Begin Joint Information Provisioning for Lenvima in Japan
October 23, 2018
- Mitsubishi Tanabe Teams Up with Bioventure for Novel Antibody Drug Discovery Research in Autoimmune Diseases
October 23, 2018
- Mundipharma Shooting for Japan Sales of US$500 Million in 10 Years: CEO
October 22, 2018
- Daiichi Sankyo Begins 1st-in-Human Trial for AXL Inhibitor
October 22, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…